Table 1.

Patient characteristics

Characteristics
Evaluable patients123
Age (median/range), y64 (26-91)
Follow-up (median/range), mo*22 (0.4-119)
FIGO stage (%)
    IA3 (2)
    IB1 (1)
    IC6 (5)
    IIB3 (2)
    IIC6 (5)
    III2 (2)
    IIIA1 (1)
    IIIB3 (2)
    IIIC88 (72)
    IV10 (8)
Histology (%)
    Papillary serous86 (70)
    Clear cell8 (7)
    Endometroid8 (7)
    Mucinous3 (2)
    Undifferentiated4 (3)
    Others (transitional, mixed, carcinosarcoma)14 (11)
Grade (%)
    15 (4)
    210 (8)
    3107 (88)
Response to frontline therapy (%)
    Complete response70 (57)
    Partial response45 (37)
    Progression3 (2)
    Unknown5 (4)
Recurrences (%)
    Recurrence/persistent disease87 (70)
Current status (%)
    Alive, NED40 (33)
    Alive with disease24 (19)
    Dead of disease59 (48)
CT antigen status by reverse transcription-PCR (%)
    SSX-1 positive3/118 (2.5)
    SSX-2 positive12/122 (10)
    SSX-4 positive19/120 (16)
    Any SSX31/120 (26)
  • * Median survival for all patients: 45 months (CI, 34-57 months).